Does CareFirst BlueCross BlueShield Cover Eliquis?

How CareFirst BlueCross BlueShield Handles Eliquis Coverage

CareFirst BCBS includes Eliquis on the majority of its commercial, individual marketplace, and Medicare Advantage Part D formularies. The drug appears as a covered brand-name medication in plan documents filed for the Maryland, D.C., and Northern Virginia service area.

Coverage does not mean zero cost. CareFirst assigns Eliquis to a specific formulary tier, and that tier determines whether you pay a flat copay or coinsurance percentage. Plans updated for the 2025-2026 benefit year generally place Eliquis on Tier 2 (preferred brand) or Tier 3 (non-preferred brand). The distinction matters: a Tier 2 copay might run $35 to $50 per fill, while Tier 3 coinsurance can reach 25% to 40% of the negotiated price. The FDA approved apixaban in 2012 for stroke prevention in non-valvular atrial fibrillation, and subsequent label expansions for deep vein thrombosis (DVT) and pulmonary embolism (PE) treatment broadened its formulary presence across all major insurers 1. According to the American College of Cardiology, direct oral anticoagulants (DOACs) like apixaban are now the default first-line therapy over warfarin for most atrial fibrillation patients 2.

Your member ID card and plan summary of benefits will confirm which tier applies. CareFirst also publishes a searchable formulary tool on its member portal.

What Eliquis Costs on a CareFirst Plan

The price you pay at the pharmacy counter depends on three variables: your plan's tier assignment, your deductible status, and whether you have met any applicable specialty cost thresholds.

For most CareFirst commercial PPO and HMO members, Eliquis copays fall between $35 and $90 per 30-day supply after the pharmacy deductible is satisfied. High-deductible health plans (HDHPs) paired with a health savings account (HSA) require you to pay the full negotiated rate until the deductible is met, which can exceed $500 for a single fill at retail. That initial sticker shock explains why many patients abandon prescriptions early. A 2023 analysis published in the Journal of the American Heart Association found that out-of-pocket costs above $50 per month were associated with a 32% increase in DOAC non-adherence among commercially insured patients 3.

Mail-order pharmacy options through CareFirst's preferred pharmacy benefit manager often reduce per-unit cost. A 90-day mail-order fill typically costs 2.0 to 2.5 times the 30-day copay rather than three times, producing savings of $12 to $30 per quarter. CareFirst members can verify mail-order eligibility through the pharmacy services section of their online account.

Medicare Advantage enrollees face a different cost structure. Under the Inflation Reduction Act's Part D redesign effective January 2025, annual out-of-pocket prescription costs are capped at $2,000 regardless of tier 4. For a CareFirst BlueCross BlueShield Medicare Advantage member taking Eliquis year-round, this cap prevents the cumulative annual cost from exceeding that threshold.

Prior Authorization and Step Therapy Requirements

Not every CareFirst plan dispenses Eliquis without extra paperwork. Some plan designs require prior authorization (PA), meaning your prescriber must submit clinical documentation before the pharmacy can fill the prescription.

PA requests typically need to confirm one of the FDA-approved indications: reduction of stroke risk in non-valvular atrial fibrillation, treatment of DVT or PE, or prophylaxis after hip or knee replacement surgery 1. CareFirst's clinical review teams evaluate these requests against criteria drawn from ACC/AHA guidelines. Approval turnaround is usually 24 to 72 hours for standard requests and under 24 hours for urgent cases.

Step therapy is less common but exists on certain cost-sensitive plans. Step therapy protocols may require documentation that the patient tried warfarin first or has a clinical reason to avoid it. The 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation explicitly recommends DOACs over warfarin for eligible patients, stating that "in patients with AF who are appropriate for oral anticoagulant therapy, a DOAC is recommended over warfarin" 2. This guideline language gives prescribers strong support when appealing step therapy denials. Denials happen. But they are usually reversible with the right documentation.

If your CareFirst plan imposes step therapy, your physician can file a formulary exception request citing the guideline recommendation, relevant bleeding risk scores (HAS-BLED), and any patient-specific contraindications to warfarin such as labile INR or drug-food interactions.

How Eliquis Compares to Other Covered Anticoagulants on CareFirst Formularies

CareFirst formularies list several anticoagulant options alongside Eliquis. Understanding the alternatives helps you discuss cost-effective choices with your prescriber if your Eliquis copay is higher than expected.

Warfarin, available as a generic, sits on Tier 1 of virtually all CareFirst plans with copays under $10 per month. The tradeoff is frequent INR monitoring, dietary restrictions, and a narrower therapeutic window. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced stroke and systemic embolism by 21% compared to warfarin (HR 0.79, 95% CI 0.66-0.95) while also lowering major bleeding by 31% (HR 0.69, 95% CI 0.60-0.80) and all-cause mortality by 11% (HR 0.89, 95% CI 0.80-0.998) 5.

Xarelto (rivarobaban) is another DOAC on most CareFirst formularies, sometimes on the same tier as Eliquis. Once-daily dosing appeals to some patients, but the RE-LY, ROCKET AF, and ARISTOTLE trials each tested different DOACs against warfarin rather than head-to-head. A network meta-analysis published in The Lancet found that apixaban had the most favorable combined profile for stroke prevention and major bleeding reduction among the four approved DOACs 6.

Savaysa (edoxaban) and Pradaxa (dabigatran) round out the DOAC class. Their CareFirst tier placement varies by plan year, and some may carry lower copays depending on rebate arrangements. Your prescriber and pharmacist can run a real-time benefit check to compare out-of-pocket costs across all four options at your specific pharmacy.

How to Verify Your CareFirst Eliquis Coverage

Confirming your exact benefit takes about five minutes. Three methods work.

Online member portal. Log in to carefirst.com, manage to "Find a Drug" or "Formulary Search," and enter "Eliquis" or "apixaban." The tool returns your plan's tier, estimated copay, and any PA or quantity limit flags. This is the fastest route.

Call member services. The number on the back of your CareFirst ID card connects you to a benefits representative who can look up your specific formulary, confirm deductible status, and tell you exactly what you will owe at the pharmacy. Ask for the drug's tier, whether PA is required, and whether mail-order pricing differs.

Ask your pharmacist. Pharmacies with real-time benefit inquiry (RTBI) technology can process a test claim that returns your actual copay before you commit to filling the prescription. The Centers for Medicare and Medicaid Services (CMS) mandated RTBI capability for Medicare Part D plans starting in 2023 7. CareFirst Medicare Advantage plans comply with this requirement.

If the quoted price seems too high, ask specifically whether a 90-day mail-order option or preferred pharmacy network would reduce your cost.

Manufacturer Copay Assistance and Other Savings Programs

Bristol-Myers Squibb and Pfizer jointly offer the Eliquis Free Trial and Savings Card program for commercially insured patients. Eligible participants pay as little as $10 per month, with the program covering up to a set annual maximum. The card cannot be used with Medicare, Medicaid, TRICARE, or other federal healthcare programs due to the Anti-Kickback Statute.

For CareFirst commercial members, stacking the manufacturer card on top of insurance often brings monthly cost to $10 regardless of tier. Enrollment requires an active prescription, commercial insurance coverage for Eliquis, and registration through the manufacturer's website or by phone. The savings card effectively neutralizes the cost difference between Tier 2 and Tier 3 placement.

Patients without commercial insurance or those on Medicare who face high out-of-pocket costs have other options. Bristol-Myers Squibb's patient assistance foundation provides free Eliquis to qualifying individuals with household incomes at or below 300% of the federal poverty level. The Medicare Part D $2,000 annual cap also reduces financial burden significantly for seniors 4.

State pharmaceutical assistance programs in Maryland may offer additional relief. The Maryland Department of Health administers the Senior Prescription Drug Assistance Program (SPDAP), which helps Medicare beneficiaries with prescription costs, including brand-name anticoagulants.

What to Do if CareFirst Denies Eliquis Coverage

A denial is not the final word. CareFirst provides a structured appeals process, and DOAC denials have a reasonable overturn rate when supported by clinical evidence.

Step 1: Get the denial in writing. CareFirst must provide a written explanation including the clinical rationale and your appeal rights. Read the specific reason. Common causes include missing prior authorization, step therapy not completed, or an off-label indication.

Step 2: File a first-level appeal. Your prescriber submits a letter of medical necessity citing the patient's diagnosis, CHA2DS2-VASc score for stroke risk, HAS-BLED score for bleeding risk, and the ACC/AHA guideline recommendation favoring DOACs over warfarin 2. Include relevant lab work and any documentation of warfarin intolerance or contraindication.

Step 3: External review. If the internal appeal fails, Maryland, D.C., and Virginia each offer independent external review through their insurance commissioner offices. The external reviewer is a physician not affiliated with CareFirst who evaluates the clinical merits. According to the Maryland Insurance Administration, external reviews overturn insurer denials in approximately 40% to 50% of prescription drug cases when clinical guidelines support the appeal 8.

During the appeal process, your prescriber can request a temporary coverage authorization so you do not go without anticoagulation. Gaps in anticoagulant therapy carry serious stroke risk. The ARISTOTLE trial demonstrated that discontinuation of anticoagulation in atrial fibrillation patients was associated with increased thromboembolic events 5.

Eliquis Dosing and Monitoring Under CareFirst Plans

CareFirst covers the two standard apixaban dosing regimens approved by the FDA. The full dose is 5 mg twice daily for most atrial fibrillation patients. The reduced dose of 2.5 mg twice daily applies to patients meeting at least two of three criteria: age 80 years or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater 1.

Quantity limits on CareFirst plans typically align with these dosing schedules: 60 tablets per 30 days for the twice-daily regimen. Requests exceeding standard quantities require PA with clinical justification.

One advantage of Eliquis over warfarin that affects long-term plan costs: routine INR monitoring is unnecessary. Warfarin-managed patients average 12 to 24 INR blood draws per year, each generating a lab claim and often a clinic visit copay. A cost-effectiveness analysis in the Annals of Internal Medicine estimated that the total annual healthcare cost for apixaban-treated atrial fibrillation patients was comparable to warfarin when factoring in monitoring, dose adjustments, and bleeding-related hospitalizations 9. This data supports coverage of DOACs even at higher tier copays because downstream costs are offset.

Your prescriber should check renal function (serum creatinine and estimated GFR) at baseline and at least annually while on Eliquis, per the 2023 ACC/AHA/ACCP/HRS guideline update. Hepatic function testing is recommended at baseline for patients with known liver disease 10.

Generic Apixaban and Future Cost Changes

No FDA-approved generic apixaban is available in the United States as of May 2026. Bristol-Myers Squibb and Pfizer hold composition-of-matter and formulation patents that have been the subject of ongoing litigation. Several generic manufacturers have filed Abbreviated New Drug Applications (ANDAs), but market entry timelines remain uncertain.

When a generic does reach the market, CareFirst and other insurers will almost certainly shift it to Tier 1 (generic) status, dropping copays to $5 to $15 per month. This pattern followed the genericization of other cardiovascular brand drugs: atorvastatin (generic Lipitor) saw a 95% price reduction within two years of generic entry 11.

Until then, the combination of CareFirst formulary coverage plus the manufacturer copay card remains the most cost-effective path for commercially insured patients. Medicare beneficiaries should factor in the $2,000 Part D cap when calculating annual anticoagulation costs and compare Eliquis against other DOACs during open enrollment each fall.